Is an ejection fraction of 45%–50% classified as heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Classification of EF 45-50%

An ejection fraction of 45-50% is classified as heart failure with mildly reduced ejection fraction (HFmrEF), not HFpEF. 1

Definitive EF Classification Thresholds

According to the 2022 AHA/ACC/HFSA guidelines, the classification is straightforward:

  • HFrEF: LVEF ≤40% 1
  • HFmrEF: LVEF 41-49% 1
  • HFpEF: LVEF ≥50% 1

Therefore, an EF of 45-50% falls squarely within the HFmrEF range (41-49%), with only EF values of exactly 50% or higher qualifying as HFpEF. 1, 2

Clinical Implications of This Classification

Why This Distinction Matters

The HFmrEF category represents patients on a dynamic trajectory—they may be improving from HFrEF or deteriorating toward it. 1 A single EF measurement at one time point is inadequate; you must evaluate the trajectory of LVEF over time and identify the underlying cause. 1

Diagnostic Requirements Beyond EF

For HFmrEF diagnosis, you need more than just the EF number and symptoms: 1, 2

  • Elevated natriuretic peptides (BNP >35 pg/mL or NT-proBNP >125 pg/mL) 2
  • Echocardiographic evidence of elevated filling pressures (E/e' ≥15) or diastolic dysfunction 1, 2
  • Structural heart disease (increased left atrial volume index or LV mass index) 1

Treatment Approach

Patients with HFmrEF should be treated similarly to HFrEF patients, as evidence suggests therapies effective in HFrEF (beta blockers, ACE inhibitors/ARBs, mineralocorticoid receptor antagonists, SGLT2 inhibitors) also benefit HFmrEF patients. 3, 4, 5

Critical Caveat

If a patient's EF improves from <40% to 45-50%, they are classified as HFimpEF (heart failure with improved EF), not HFmrEF. 1 These patients should continue HFrEF treatment despite the improved EF, as discontinuation can lead to deterioration. 1 The guideline explicitly notes uncertainty about how to treat patients who improve from HFmrEF (41-49%) to ≥50%. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Classification and Diagnosis of Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.